Results 241 to 250 of about 38,450 (306)

T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges. [PDF]

Cell Rep Med
Paczesny S, Barwe SP, Gopalakrishnapillai A, Cheung NV.   +3 more
europepmc   +1 more source

Bispecific antibodies targeting herpes simplex virus glycoproteins B and D. [PDF]

Front Immunol
Atanasiu D, Saw WT, Cairns TM, Friedman HM, Cohen GH.   +4 more
europepmc   +1 more source

Advances in translational lung cancer research in 2025: a narrative review. [PDF]

Transl Lung Cancer Res
Xu Y, Kuang Y, Guo Y, Lou Y.
europepmc   +1 more source

Antibody targeting of the TNF-TNFR2 axis to overcome tumor immune resistance. [PDF]

Front Immunol
Kang X, Tong X, Wang S.
europepmc   +1 more source

A conditional multi-signal validation framework for cancer immunotherapy: the adaptive anti-error biological system. [PDF]

Front Immunol
Kalondero EM.
europepmc   +1 more source

Transitioning CAR‐T therapy for multiple myeloma to the outpatient setting: First clinical insights with cilta‐cel in Germany

HemaSphere, Volume 10, Issue 7, July 2026.
Christof Scheid, Philipp Gödel, Christopher Krone, Elisa Carpinteiro, Michael Hallek, Udo Holtick, Tim Richardson   +6 more
wiley   +1 more source

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T‐Cell Immunotherapy for B‐Cell Malignancies: A Case Series

Hematological Oncology, Volume 44, Issue 4, July 2026.
Gianluca Cavallaro, Silvia Ferrari, Anna Pollastri, Elena Di Credico, Cristian Meli, Monica Rondi, Alessandro Putelli, Federico Lussana, Anna Grassi, Alessandro Rambaldi, Tino Martino Valetti, Ivano Riva, Giuseppe Gritti   +12 more
wiley   +1 more source

Abstracts for the 2026 Immunotherapy and Precision Oncology Forum: April 11, 2026, Cincinnati, OH, USA. [PDF]

J Immunother Precis Oncol
europepmc   +1 more source